Home › News › Tirzepatide Combination Therapy Trials: Four New Add-On Studies

Tirzepatide Combination Therapy Trials: Four New Add-On Studies

August 13, 2026 · 7 sources · 4 min read

Healthcare worker in scrubs reviewing patient files with a stamp and clipboard. — Article illustration for a report on tirzepatide combination therapy trials registered in August 2026 — Photo: https://kaboompics.com/ / Pexels

Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.

Tirzepatide and semaglutide are now background therapy in a wave of combination trials rather than the comparator. Four industry-sponsored studies updated on ClinicalTrials.gov between August 10 and 13, 2026 — from Alnylam, Roche, Cascade Pharmaceuticals and Novo Nordisk — test investigational agents added on top of an already-approved incretin drug.

The short version

Four ClinicalTrials.gov records updated between August 10 and 13, 2026 describe investigational agents given alongside tirzepatide or semaglutide rather than compared against them.
Roche's Phase 2 study of RO7204239 enrolls 285 adults, runs a 48-week core period with tirzepatide as background treatment, then stops tirzepatide for a 24-week extension.
Alnylam's Phase 1/2 study of ALN-2232 in 156 participants with obesity includes an arm in which the investigational agent is co-initiated with tirzepatide.
Semaglutide is the backbone in a Phase 2 MASH trial of CS060380 tablets and a Phase 1 type 1 diabetes study of Novo Nordisk's NNC0194-0499.
Novo Nordisk is separately running a Phase 2 study of UBT251 with semaglutide as an active comparator, a different bet than combining agents.

What the registry updates actually show

Between August 10 and 13, 2026, ClinicalTrials.gov posted or refreshed records for a group of obesity and metabolic trials that share one structural feature: the approved incretin drug is not the thing being tested. Tirzepatide or semaglutide is given to everyone as background therapy, and the question is whether an investigational agent layered on top produces something the incretin alone did not.

That is a meaningful shift in how the field frames its questions. The pivotal trials that brought semaglutide and tirzepatide to market compared drug against placebo. The studies now entering or finishing enrollment compare drug-plus-something against drug-plus-placebo, which sets a far higher bar for the newcomer and treats the incretin backbone as standard of care.

Why tirzepatide combination therapy trials look different from earlier obesity studies

Alnylam Pharmaceuticals is recruiting 156 participants with obesity into a Phase 1/2 study of ALN-2232. According to the registry record, the trial has three objectives: safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of single ascending doses; the same measures across multiple doses; and the same measures again when multiple doses are co-initiated with tirzepatide. Pharmacokinetics describes how the body handles a drug; pharmacodynamics describes what the drug does to the body.

The co-initiation arm is the notable part. Rather than adding an agent to people already stable on tirzepatide, Alnylam is starting both at once — a design that reads more like an early attempt at a fixed regimen than a rescue strategy for people who have plateaued. The record lists the study as Phase 1/2, meaning first-in-patient safety work and early efficacy signals are being collected in the same protocol.

If you are tracking a provider-directed regimen alongside this news, the tirzepatide dosage calculator handles the unit arithmetic that trial records deliberately omit.

Roche's Phase 2 study takes tirzepatide away on purpose

Hoffmann-La Roche's Phase 2 trial of RO7204239 is listed as active but no longer recruiting, with 285 adults who have obesity or overweight plus at least one weight-related comorbidity and no diabetes. The stated main aim is the effect of RO7204239 combined with tirzepatide, versus placebo combined with tirzepatide, on body weight after 48 weeks. All four randomized arms receive tirzepatide as background treatment during that core period.

What sets the design apart is what comes after. The record describes a 4-week screening period, the 48-week core, then a 24-week extension in which participants stop tirzepatide, followed by a 24-week post-treatment follow-up. In other words, the trial is built to observe what happens when the incretin is withdrawn while the investigational agent continues — a direct test of whether an add-on changes the trajectory after discontinuation.

For protocols built on the other backbone drug named in these studies, the semaglutide dosage calculator covers the same ground.

The discontinuation question is being studied from several directions

Weight regain after stopping incretin-based therapy is one of the most-asked questions among people on these protocols, and it is being approached from more than one angle in the current literature. A narrative review by Zeigler and colleagues published in Healthcare examined structured exercise during and after discontinuation of incretin-based pharmacotherapy, covering proposed mechanisms, the state of the evidence and prescription guidance. A narrative review is a synthesis of existing work by its authors, not new trial data.

Read alongside the Roche design, the two illustrate the same underlying uncertainty: nobody yet has strong controlled evidence about what preserves the result once the drug stops. One line of inquiry asks whether a second pharmacologic agent can hold the line; the other asks whether structured physical activity can. Neither has produced a definitive answer.

Combination protocols add variables, which is exactly the situation where consistent side-effect logging makes a timeline usable to a clinician.

Semaglutide as backbone: MASH and type 1 diabetes

Cascade Pharmaceuticals is running a Phase 2 trial of CS060380 tablets in 130 adults with both metabolic dysfunction-associated steatohepatitis, or MASH, and obesity. MASH is a condition in which fat accumulation in the liver drives inflammation and damage. Per the registry record, the study includes a screening period of up to two weeks, a 36-week double-blind period in which participants receive CS060380 or placebo — with everyone also receiving semaglutide — and a 16-week open-label period in which all participants receive the investigational tablet.

Novo Nordisk's own pipeline shows the same pattern outside obesity. A Phase 1 study of NNC0194-0499, listed as active and not recruiting with 96 participants, is testing the compound's effect on blood glucose in people with type 1 diabetes when taken in combination with semaglutide or with placebo. All participants continue standard-of-care insulin treatment, and the study is expected to run about 36 weeks.

Roche's registry record for RO7204239 lists 285 participants, a 48-week core treatment period with tirzepatide as background therapy, and a 24-week extension in which tirzepatide is stopped.

The alternative bet: one molecule instead of two drugs

Not every sponsor is stacking agents. Novo Nordisk is also recruiting 300 participants with type 2 diabetes into a Phase 2 study of UBT251, randomizing them to UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. The registry record describes UBT251 as not yet available for prescription and identifies semaglutide as a medicine doctors can already prescribe, positioning the trial as a head-to-head efficacy and safety comparison rather than an add-on.

Tirzepatide is meanwhile being pushed into new indications on its own. The National Institute on Alcohol Abuse and Alcoholism is recruiting 120 people aged 21 and older with alcohol use disorder and metabolic alcohol-associated liver disease, or MetALD, into a Phase 2 study that includes liver stiffness measurement by Fibroscan and evaluates a weekly subcutaneous regimen over 12 weeks. That trial tests tirzepatide alone, not in combination.

The ALN-2232 study listing describes an arm evaluating multiple doses co-initiated with tirzepatide in patients with obesity. the ALN-2232 study listing.

What remains unresolved

None of these records contain results. Registry entries describe design, enrollment and status; they do not report outcomes, and several of the compounds named here have no published human efficacy data at all. The Roche and Cascade studies are listed as active but closed to new participants, which means data readouts are plausible in the coming year, while the Alnylam and UBT251 studies are still enrolling.

The registry records also do not describe how these investigational agents work. Sponsors frequently withhold mechanism detail from public listings, so the honest summary is that four companies believe an approved incretin is now the floor rather than the ceiling, and that they are willing to spend Phase 2 money finding out whether anything meaningfully clears it.

The UBT251 Phase 2 record shows 300 participants with type 2 diabetes randomized to UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. the UBT251 Phase 2 record.

What this means if you're tracking a protocol

For anyone tracking a provider-directed tirzepatide or semaglutide protocol, the practical takeaway is that the drug already in your log is increasingly the comparator arm of record. If a provider raises the possibility of a trial, these designs mean the incretin usually continues rather than stopping — and in the Roche study, a planned withdrawal period is part of the protocol, not an interruption. Knowing which structure a study uses changes what a participant would be recording and for how long.

There is also a records angle worth noting. Combination and add-on protocols multiply the number of variables in a log: two agents with different schedules, an open-label switch partway through, or a stretch with no incretin at all. People who already keep a consistent side-effect log and an accurate history of what they took and when are in a much better position to give a study coordinator or a treating clinician a usable timeline. Nothing here suggests changing an existing protocol; it is a reason to keep the existing one documented cleanly.

Frequently asked questions

Does an add-on trial mean tirzepatide alone is not effective enough?

No. Using tirzepatide as background therapy in all arms means the sponsor accepts it as the standard against which an addition must prove itself. Roche's Phase 2 study of RO7204239 compares RO7204239 plus tirzepatide against placebo plus tirzepatide in 285 adults, so any benefit measured is benefit beyond what tirzepatide already delivers, not a replacement for it.},{

What does the RO7204239 trial's tirzepatide withdrawal period test?

The registry record describes a 24-week extension after the 48-week core period in which participants stop tirzepatide, followed by 24 weeks of post-treatment follow-up. That structure lets investigators observe what happens to body weight once the incretin is removed while the investigational agent continues. No results have been published, and the study is listed as active but not recruiting.

Is UBT251 a combination therapy like the others?

No. In the Phase 2 trial Novo Nordisk is recruiting, 300 participants with type 2 diabetes are randomized to UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Semaglutide functions as an active comparator rather than a backbone given to everyone, making this a head-to-head effectiveness and safety study rather than an add-on design.

When will results from these combination trials be available?

The records do not give readout dates. The Roche RO7204239 study and Cascade's CS060380 MASH study are both listed as active and not recruiting, which typically means follow-up is underway; Cascade's protocol runs up to 54 weeks in total. Alnylam's ALN-2232 study and Novo Nordisk's UBT251 study were still recruiting as of mid-August 2026.

Sources

A Study to Evaluate ALN-2232 in Participants With Obesity
ClinicalTrials.gov · August 12, 2026
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
ClinicalTrials.gov · August 11, 2026
A Study of CS060380 Tablets in Patients With MASH and Obesity
ClinicalTrials.gov · August 10, 2026
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
ClinicalTrials.gov · August 13, 2026
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
ClinicalTrials.gov · August 10, 2026
Tirzepatide in MetALD
ClinicalTrials.gov · August 12, 2026
Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance
Healthcare (Basel, Switzerland) via PubMed

How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

← Back to all peptide news